Technical Analysis for SABS - SAB Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.10 | 0.24% | 0.01 |
Earnings due: May 14
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 0.24% | |
| Slingshot Bearish | Bearish Swing Setup | 0.24% | |
| Stochastic Buy Signal | Bullish | 0.24% | |
| Pocket Pivot | Bullish Swing Setup | 0.24% | |
| Gapped Up | Strength | 0.24% | |
| Oversold Stochastic | Weakness | 0.24% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 10 hours ago |
| Rose Above 20 DMA | about 12 hours ago |
| Up 5% | about 12 hours ago |
| 60 Minute Opening Range Breakout | about 12 hours ago |
| Rose Above 10 DMA | about 12 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/14/2024
SAB Biotherapeutics, Inc. Description
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Diabetes Infectious Diseases Antibodies Autoimmune Disease Antibody Immunotherapies Influenza Genetic Engineering Us Government Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.5 |
| 52 Week Low | 3.94 |
| Average Volume | 12,795 |
| 200-Day Moving Average | 6.61 |
| 50-Day Moving Average | 4.61 |
| 20-Day Moving Average | 4.31 |
| 10-Day Moving Average | 4.10 |
| Average True Range | 0.28 |
| RSI (14) | 42.86 |
| ADX | 17.25 |
| +DI | 30.92 |
| -DI | 16.24 |
| Chandelier Exit (Long, 3 ATRs) | 4.10 |
| Chandelier Exit (Short, 3 ATRs) | 4.78 |
| Upper Bollinger Bands | 4.81 |
| Lower Bollinger Band | 3.81 |
| Percent B (%b) | 0.29 |
| BandWidth | 23.23 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.17 |
| MACD Histogram | -0.0021 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.47 | ||||
| Resistance 3 (R3) | 4.51 | 4.43 | 4.41 | ||
| Resistance 2 (R2) | 4.43 | 4.34 | 4.41 | 4.39 | |
| Resistance 1 (R1) | 4.27 | 4.28 | 4.22 | 4.22 | 4.37 |
| Pivot Point | 4.18 | 4.18 | 4.16 | 4.16 | 4.18 |
| Support 1 (S1) | 4.02 | 4.09 | 3.98 | 3.98 | 3.83 |
| Support 2 (S2) | 3.93 | 4.03 | 3.91 | 3.81 | |
| Support 3 (S3) | 3.77 | 3.93 | 3.79 | ||
| Support 4 (S4) | 3.73 |
